U.S. MARKET FOR MINIMALLY INVASIVE BARIATRIC SURGICAL DEVICES

232 Pages | 87 Exhibits | 2011 Analysis | Forecasts Through 2016 Product Family: Market Reports




OVERVIEW:
An estimated 200 million adults in the U.S. (a staggering 68% of the adult population) are categorized as overweight or obese. Obesity is the, second-leading cause of preventable death in the U.S. resulting in nearly 112,000 deaths annually. The condition is a leading cause of type 2 diabetes, disability, and heart disease, and is a significant contributor to rising healthcare costs. Despite the dire need for weight loss in the majority of the adult population, research has found that diet and exercise alone is unsuccessful in 80-85% of patients at one year, and only approximately 1% of the eligible obese population currently undergoes bariatric surgery due to high cost and high risk of complications. This presents a significant unmet need for less invasive weight loss treatments. Although more clinical research is required, minimally invasive bariatric surgical devices and systems may provide a less costly, safe and effective-and potentially lifesaving-weight loss alternative.

While current economic conditions continue to restrain market growth, the U.S. market for minimally invasive bariatric surgical devices is expected to exhibit relatively strong growth over the next 5 years. Valued at more than $345 million in 2010, the U.S. minimally invasive bariatric surgical products market is expected to increase at a healthy compound annual rate of 6.6%, with sales reaching more than $500 million in 2016.

The market is expected to benefit from increased utilization of laparoscopic adjustable gastric banding systems and emerging incisionless technologies, including intragastric balloons and other transorally inserted weight loss devices, as well as implantable gastric stimulators or vagal blocking systems. The market is also expected to benefit from growing usage of single-incision surgery; minimally invasive robotic surgery is also expected to continue to significantly improve bariatric surgical outcomes.

This dynamic report from Medtech Insight includes analyses of products, markets, competitors, and emerging technology and opportunities. Covered topics in this report include laparoscopic adjustable gastric banding (LAGB) systems; intragastric balloon systems; emerging transorally inserted weight loss devices; single-incision technologies; minimally invasive robotic systems; and implantable gastric stimulation/vagal blocking systems.

TABLE OF CONTENTS:
EXECUTIVE SUMMARY

i. Causes of Obesity 
ii. Health Risks 
iii. Statistics 
iv. Minimally Invasive Bariatric Surgical Devices Market 
v. Methodology 

Exhibit ES-1: Body Mass Index and Obesity 
Exhibit ES-2: Surgeon General's Call to Action to Prevent and Decrease Overweight and Obesity 
Exhibit ES-3: Trends in Overweight, Obesity, and Morbid Obesity, 1988-2008 
Exhibit ES-4: Trends in Overweight, Obesity, and Morbid Obesity, 1960-2008 
Exhibit ES-5: Prevalence of Obesity Among Men, by Race/Ethnicity, 1988-1994 and 2007-2008 
Exhibit ES-6: Prevalence of Obesity Among Women, by Race/Ethnicity, 1988-1994 and 2007-2008 
Exhibit ES-7: Minimally Invasive Bariatric Surgery, Procedure Volumes Forecast, 2010-2016 
Exhibit ES-8: Minimally Invasive Bariatric Surgical Devices, Combined Market Forecast, by Segment, 2010-2016 

1. CLINICAL OVERVIEW OF OBESITY

1.1 Causes of Obesity 
	1.1.1 Calorie Intake 
	1.1.2 Genetics 
	1.1.3 Behavior and Environment 
	1.1.4 Diseases/Disorders and Drug Use 
1.2 Health Risks 
	1.2.1 Diabetes 
	1.2.2 Cancer 
1.3 Statistics 

Exhibit 1-1: Body Mass Index and Obesity 
Exhibit 1-2: Surgeon General's Call to Action to Prevent and Decrease Overweight and Obesity 
Exhibit 1-3: Comorbidities of Obesity 
Exhibit 1-4: Trends in Overweight, Obesity, and Morbid Obesity, 1988-2008 
Exhibit 1-5: Trends in Overweight, Obesity, and Morbid Obesity, 1960-2008 
Exhibit 1-6: Prevalence of Obesity Among Men, by Race/Ethnicity,  1988-1994 and 2007-2008 
Exhibit 1-7: Prevalence of Obesity Among Women, by Race/Ethnicity, 1988-1994 and 2007-2008 
Exhibit 1-8: 2007, Prevalence of Obesity Among Adults, by State 

2. GASTRIC BANDING AND INTRAGASTRIC BALLOON SYSTEMS

2.1 Laparoscopic Adjustable Gastric Banding
	2.1.1 Allergan 
	2.1.2 Ethicon Endo-Surgery/Johnson & Johnson 
	2.1.3 Others 
		2.1.3.1 Agency for Medical Innovations 
		2.1.3.2 Cousin Biotech 
		2.1.3.3 Helioscopie 
		2.1.3.4 Medical Innovation Developpement 
2.2 Intragastric Balloons 
	2.2.1 Allergan 
	2.2.2 Helioscopie 
	2.2.3 Reshape Medical 
	2.2.4 Spatz FGIA 
2.3 Market Analysis, Laparoscopic Adjustable Gastric Banding 
	2.3.1 Procedure Volumes Forecast 
	2.3.2 Market Forecast 
		2.3.2.1 Market Drivers 
		2.3.2.2 Market Limiters 
	2.3.3 Competitive Analysis 
2.4 Market Analysis, Intragastric Balloon Systems 

Exhibit 2-1: Risks Associated with Gastric Banding and Abdominal/Bariatric Surgery 
Exhibit 2-2: 2011, Selected Laparoscopic Adjustable Gastric Banding Devices 
Exhibit 2-3: Allergan's LAP-BAND AP Adjustable Gastric Banding System 
Exhibit 2-4: Key Benefits and Risks of the LAP-BAND Procedure 
Exhibit 2-5: Excess Weight Loss with the LAP-BAND System Compared to Roux-en-Y Gastric Bypass at Three Years and Beyond 
Exhibit 2-6: Allergan's EasyBand Remote Adjustable Gastric Band System 
Exhibit 2-7: Ethicon Endo-Surgery's Realize Adjustable Gastric Band 
Exhibit 2-8: Pressure Comparison of the Realize Band Balloon with the LAP-BAND System 
Exhibit 2-9: Comparison of Gastric Banding, Gastric Bypass, and Sleeve Gastrectomy 
Exhibit 2-10: Effects of the Realize Adjustable Gastric Banding on  Obesity-Related Conditions 
Exhibit 2-11: Ethicon Endo-Surgery's Realize Band-C Adjustable Gastric Band 
Exhibit 2-12: Agency for Medical Innovations' Soft Gastric Band 
Exhibit 2-13: Cousin Biotech's Bioring Adjustable Gastric Band 
Exhibit 2-14: Helioscopie's Heliogast Adjustable Gastric Band 
Exhibit 2-15: Medical Innovation Developpement's MIDBAND Adjustable Gastric Band 
Exhibit 2-16: Allergan's Orbera Managed Weight Loss System 
Exhibit 2-17: Helioscopie's Heliosphere Intragastric Balloon 
Exhibit 2-18: ReShape Duo Intragastric Balloon System 
Exhibit 2-19: The Spatz Adjustable Balloon System 
Exhibit 2-20: Risks of Intragastric Balloon Placement 
Exhibit 2-21: The Spatz Adjustable Balloon Procedure 
Exhibit 2-22: Laparoscopic Adjustable Gastric Banding, Procedure Volumes Forecast, 2010-2016 
Exhibit 2-23: Laparoscopic Adjustable Gastric Banding, Market Forecast, 2010-2016 
Exhibit 2-24: 2010, Laparoscopic Adjustable Gastric Banding Systems Market, Share by Supplier 
Exhibit 2-25: Intragastric Balloon Therapy, Procedure Volumes Forecast, 2010-2016 
Exhibit 2-26: Intragastric Balloon Systems,  Market Forecast, 2010-2016 

3. TRANSORAL INCISIONLESS WEIGHT LOSS TECHNOLOGIES AND DEVICES

3.1 Selected Products 
	3.1.1 EndoGastric Solutions 
	3.1.2 GI Dynamics 
	3.1.3 Satiety 
	3.1.4 USGI Medical 

Exhibit 3-1: Emerging Trends in Minimally Invasive/Incisionless Surgery 
Exhibit 3-2: EndoGastric Solutions' StomaphyX Transoral Fastener Delivery System 
Exhibit 3-3: GI Dynamic's EndoBarrier Gastrointestinal Liner and Procedure 
Exhibit 3-4: GI Dynamic's EndoBarrier Gastrointestinal Liner Combined with the EndoBarrier Flow Restrictor 
Exhibit 3-5: Steps of a Transoral Gastroplasty (or TOGA) Procedure 
Exhibit 3-6: USGI Medical's Incisionless Operating Platform 
Exhibit 3-7: Primary Obesity Surgery, Endolumenal and  Repair of Surgery, Endolumenal 

4. SINGLE-PORT ACCESS SURGERY

4.1 Single-Incision Bariatric Surgery 
4.2 Natural Orifice Transluminal Endoscopic Surgery 
4.3 Procedure Volumes 
4.4 Patient Outcomes 
4.5 Economics and Consumer Demand 
4.6 Selected Products 
	4.6.1 Applied Medical Resources 
	4.6.2 Covidien 
	4.6.3 Ethicon Endo-Surgery/Johnson & Johnson 
	4.6.4 Olympus America/Olympus and Advanced Surgical Concepts 
	4.6.5 TransEnterix 
	4.6.6 USGI Medical 

Exhibit 4-1: Selected Advantages of Single-Port Access Surgery 
Exhibit 4-2: Procedures Employing Single-Port Access 
Exhibit 4-3: Selected Laparoscopic Procedures that Could Benefit from the Use of Single-Port Access, Procedure Volumes Forecast, 2010-2016 
Exhibit 4-4: Factors Impacting the Adoption of Single-Port Access Surgery 
Exhibit 4-5: Applied Medical Resources' GelPOINT Advanced Access Platform 
Exhibit 4-6: Applied Medical Resources' Premium Disposable Trocar, Kii GelPort Balloon Trocar, and Universal Seal 
Exhibit 4-7: Covidien's SILS Port 
Exhibit 4-8: Covidien's SILS Stitch Articulating Suturing Device 
Exhibit 4-9: Ethicon Endo-Surgery's ENDOPATH XCEL Bladeless Trocar 
Exhibit 4-10: Ethicon Endo-Surgery's Single-Site Laparoscopy Access System 
Exhibit 4-11: Olympus America's Deflectable-Tip EndoEYE  Video Laparoscope 
Exhibit 4-12: Advanced Surgical Concepts' TriPort Multiport Access Device 
Exhibit 4-13: Advanced Surgical Concepts' QuadPort Multiport Access Device 
Exhibit 4-14: TransEnterix's SPIDER Surgical System 
Exhibit 4-15: USGI Medical's Incisionless Operating Platform 

5. ROBOTIC-ASSISTED MINIMALLY INVASIVE SURGERY

5.1 Intuitive Surgical 
	5.1.1 The da Vinci Surgical System 
		5.1.1.1 The Da Vinci Gastric Bypass 
	5.1.2 Robotic-Assisted Minimally Invasive Surgery, Market Analysis 

Exhibit 5-1: Selected Procedures Facilitated by the da Vinci Surgical System 
Exhibit 5-2: Intuitive Surgical's da Vinci S HD Surgical System 
Exhibit 5-3: Intuitive Surgical's da Vinci Si HD Surgical System 
Exhibit 5-4: Intuitive Surgical's EndoWrist Instrument 
Exhibit 5-5: Comparison of the da Vinci Gastric Bypass Procedure with the Open Surgical Technique 
Exhibit 5-6: Intuitive Surgical's Revenues and Unit Sales, 2009 and 2010 
Exhibit 5-7: Procedures that Employ Intuitive Surgical's da Vinci Surgical System 
Exhibit 5-8: Targeted Procedures for which the da Vinci Surgical System May Be Employed 
Exhibit 5-9: Robotic-Assisted Minimally Invasive Surgical Systems, Market Forecast, 2010-2016 

6. IMPLANTABLE GASTRIC STIMULATION DEVICES

6.1 Selected Products 
	6.1.1 EnteroMedics 
	6.1.2 IntraPace 
	6.1.3 MetaCure 
	6.1.4 Others 
		6.1.4.1 Cyberonics and Ethicon Endo-Surgery/Johnson & Johnson 
		6.1.4.2 Leptos Biomedical 
		6.1.4.3 Medtronic 
		6.1.4.4 St. Jude Medical 
6.2 Market Analysis 

Exhibit 6-1: 2011, Selected Emerging Implantable Pulse Generators for the Treatment of Obesity 
Exhibit 6-2: EnteroMedics' Maestro System 
Exhibit 6-3: Overview of EnteroMedics' VBLOC Therapy and Vagus Nerve Function 
Exhibit 6-4: Potential Benefits and Risks of VBLOC Therapy 
Exhibit 6-5: Comparison of VBLOC Therapy, Laparoscopic Banding, and Gastric Bypass 
Exhibit 6-6: EMPOWER Study, 24-Month Weight Loss Results 
Exhibit 6-7: VBLOC-DM2 Study, 12-Month Weight Loss Results 
Exhibit 6-8: VBLOC RF2 Study, 24-Month Weight Loss Results 
Exhibit 6-9: IntraPace's abiliti Gastric Stimulation System 
Exhibit 6-10: MetaCure's TANTALUS Gastric Stimulation System 
Exhibit 6-11: Medtronic's Enterra Neurostimulator 
Exhibit 6-12: St. Jude Medical's Eon Mini Neurostimulator 
Exhibit 6-13: Implantable Gastric Stimulation/VBLOC Therapy Devices,  Unit Sales Forecast, 2010-2016 
Exhibit 6-14: Implantable Gastric Stimulation/VBLOC Therapy Devices, Market Forecast, 2010-2016 

7. COMPANY PROFILES

7.1 Allergan, Inc. 
7.2 Covidien PLC 
7.3 EndoGastric Solutions, Inc. 
7.4 EnteroMedics, Inc. 
7.5 GI Dynamics, Inc. 
7.6 Intuitive Surgical, Inc. 
7.7 Johnson & Johnson 
7.8 ReShape Medical, Inc. 
7.9 Satiety, Inc. 
7.10 Spatz FGIA, Inc. 
7.11 TransEnterix, Inc. 
7.12 USGI Medical, Inc. 


APPENDIX:  COMPANY LISTING


COMPANIES COVERED:

  1. Allergan, Inc.
  2. Covidien PLC
  3. EndoGastric Solutions, Inc.
  4. EnteroMedics, Inc.
  5. GI Dynamics, Inc.
  6. Intuitive Surgical, Inc.
  7. Johnson & Johnson
  8. ReShape Medical, Inc.
  9. Satiety, Inc.
  10. Spatz FGIA, Inc.
  11. TransEnterix, Inc.
  12. USGI Medical, Inc.
Contact Us

Need help finding medtech research? Let us help you!